In a large multinational series of NSCLC, the prevalence of EGFR mutation was 27% and 34% in Taiwanese and Japanese NSCLC patients, respectively, and only 14% and 7% in US and Australian NSCLC patients, respectively.11 A percentage of EGFR mutations as high as 61% was noted in Taiwanese samples from clinical trials.10,12,28 EGFR inhibitors not only increased the response rate of lung cancers with EGFR mutations but also prolonged the progression-free survival and overall survival. This evidence concerns the gene EGFR and lung carcinoma.